1. Home
  2. APC vs DSGN Comparison

APC vs DSGN Comparison

Compare APC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ARKO Petroleum Corp. Class A Common Stock

APC

ARKO Petroleum Corp. Class A Common Stock

N/A

Current Price

$18.84

Market Cap

884.3M

Sector

Energy

ML Signal

N/A

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$15.68

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APC
DSGN
Founded
2025
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
884.3M
853.8M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
APC
DSGN
Price
$18.84
$15.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$21.75
$15.25
AVG Volume (30 Days)
147.7K
456.7K
Earning Date
05-11-2026
04-28-2026
Dividend Yield
10.99%
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
N/A
N/A
Revenue This Year
$4.47
N/A
Revenue Next Year
$4.20
N/A
P/E Ratio
$40.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.08
$5.04
52 Week High
$21.72
$17.25

Technical Indicators

Market Signals
Indicator
APC
DSGN
Relative Strength Index (RSI) 40.36 64.06
Support Level $17.65 $9.78
Resistance Level $19.49 $15.86
Average True Range (ATR) 0.65 0.62
MACD -0.09 0.10
Stochastic Oscillator 16.40 75.29

Price Performance

Historical Comparison
APC
DSGN

About APC ARKO Petroleum Corp. Class A Common Stock

Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: